Current Concepts on Gastric Carcinoid Tumors

Overview

Journal Gastroenterol Res Pract

Publisher Wiley

Specialty Gastroenterology

Date 2013 Jan 15

PMID 23316222

Citations 32

Authors

George C Nikou

Theodoros P Angelopoulos

Affiliations

Soon will be listed here.

Abstract

Gastric carcinoid tumors (GCs) are rare lesions representing less than 10% of carcinoid tumors and less than 1% of all stomach neoplasms. There are three distinct types of gastric carcinoids; type I includes the vast majority (70-85%) of these neoplasms that are closely linked to chronic atrophic gastritis. Type II which accounts for 5-10 %, is associated with Zollinger-Ellison syndrome and often occurs in the context of multiple endocrine neoplasia type 1. Type III, finally, represents 15-25% of gastric carcinoids and is characterized by a far more aggressive course. The optimal clinical approach to GCs remains to be elucidated, depending upon type, size, and number of carcinoids. While there is universal agreement about the surgical treatment of type III GCs, current options for type I and II include simple surveillance, endoscopic polypectomy, surgical excision associated with or without surgical antrectomy, or total gastrectomy. Moreover, the introduction of somatostatin analogues could represent another therapeutic option.

Citing Articles

GASTRIC NEUROENDOCRINE TUMOR: WHEN SURGICAL TREATMENT IS INDICATED?.

Assis Filho A, Tercioti Junior V, Andreollo N, Ferrer J, Coelho Neto J, Lopes L Arq Bras Cir Dig. 2023; 36:e1768.

PMID: 37851754 PMC: 10578147. DOI: 10.1590/0102-672020230050e1768.

Relation between WHO Classification and Location- and Functionality-Based Classifications of Neuroendocrine Neoplasms of the Digestive Tract.

Helderman N, Suerink M, Kilinc G, van den Berg J, Nielsen M, Tesselaar M Neuroendocrinology. 2023; 114(2):120-133.

PMID: 37690447 PMC: 10836754. DOI: 10.1159/000534035.

Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors.

Sebastian-Valles F, Bernaldo Madrid B, Sager C, Carrillo Lopez E, Mera Carreiro S, Avila Anton L Biomedicines. 2023; 11(3).

PMID: 36979851 PMC: 10045480. DOI: 10.3390/biomedicines11030872.

A rare case of an enterochromaffin-like neuroendocrine tumor associated with parietal cell dysfunction treated using endoscopic submucosal dissection.

Shiroma S, Higuchi K, Ota H, Umeno J, Ishioka M, Hirasawa T Clin J Gastroenterol. 2022; 15(6):1041-1047.

PMID: 36125703 DOI: 10.1007/s12328-022-01704-7.

Multiple endocrine neoplasia 1: a broad overview.

Thompson R, Landry C Ther Adv Chronic Dis. 2021; 12:20406223211035288.

PMID: 34413971 PMC: 8369854. DOI: 10.1177/20406223211035288.

References

Gibril F, Reynolds J, Lubensky I, Roy P, Peghini P, Doppman J . Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J Nucl Med. 2000; 41(10):1646-56. View

Metz D . Diagnosis of the Zollinger–Ellison syndrome. Clin Gastroenterol Hepatol. 2011; 10(2):126-30. DOI: 10.1016/j.cgh.2011.07.012. View

Lawrence B, Kidd M, Svejda B, Modlin I . A clinical perspective on gastric neuroendocrine neoplasia. Curr Gastroenterol Rep. 2010; 13(1):101-9. DOI: 10.1007/s11894-010-0158-4. View

Nikou G, Toubanakis C, Moulakakis K, Pavlatos S, Kosmidis C, Mallas E . Carcinoid tumors of the duodenum and the ampulla of Vater: current diagnostic and therapeutic approach in a series of 8 patients. Case series. Int J Surg. 2011; 9(3):248-53. DOI: 10.1016/j.ijsu.2010.12.003. View

Okita N, Kato K, Takahari D, Hirashima Y, Nakajima T, Matsubara J . Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer. 2011; 14(2):161-5. DOI: 10.1007/s10120-011-0025-5. View

Modlin I, Lye K, Kidd M . A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem?. Am J Gastroenterol. 2003; 99(1):23-32. DOI: 10.1046/j.1572-0241.2003.04027.x. View

Powell A, Libutti S . Multiple endocrine neoplasia type 1: clinical manifestations and management. Cancer Treat Res. 2009; 153:287-302. DOI: 10.1007/978-1-4419-0857-5_16. View

Fossmark R, Sordal O, Jianu C, Qvigstad G, Nordrum I, Boyce M . Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012; 36(11-12):1067-75. DOI: 10.1111/apt.12090. View

Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L . Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005; 242(1):64-73. PMC: 1357706. DOI: 10.1097/01.sla.0000167862.52309.7d. View

10.

Nikou G, Toubanakis C, Nikolaou P, Giannatou E, Marinou K, Safioleas M . Gastrinomas associated with MEN-1 syndrome: new insights for the diagnosis and management in a series of 11 patients. Hepatogastroenterology. 2005; 52(66):1668-76. View

11.

Bushnell D, Baum R . Standard imaging techniques for neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011; 40(1):153-62, ix. DOI: 10.1016/j.ecl.2010.12.002. View

12.

Klimstra D, Modlin I, Coppola D, Lloyd R, Suster S . The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010; 39(6):707-12. DOI: 10.1097/MPA.0b013e3181ec124e. View

13.

Karaca C, Turner B, Cizginer S, Forcione D, Brugge W . Accuracy of EUS in the evaluation of small gastric subepithelial lesions. Gastrointest Endosc. 2010; 71(4):722-7. DOI: 10.1016/j.gie.2009.10.019. View

14.

Lehy T, Roucayrol A, Mignon M . Histomorphological characteristics of gastric mucosa in patients with Zollinger-Ellison syndrome or autoimmune gastric atrophy: role of gastrin and atrophying gastritis. Microsc Res Tech. 2000; 48(6):327-38. DOI: 10.1002/(SICI)1097-0029(20000315)48:6<327::AID-JEMT3>3.0.CO;2-L. View

15.

Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

16.

Gencosmanoglu R, Sen-Oran E, Kurtkaya-Yapicier O, Avsar E, Sav A, Tozun N . Gastric polypoid lesions: analysis of 150 endoscopic polypectomy specimens from 91 patients. World J Gastroenterol. 2003; 9(10):2236-9. PMC: 4656470. DOI: 10.3748/wjg.v9.i10.2236. View

17.

Norton J, Melcher M, Gibril F, Jensen R . Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2005; 136(6):1267-74. DOI: 10.1016/j.surg.2004.06.057. View

18.

Kidd M, Gustafsson B . Management of gastric carcinoids (neuroendocrine neoplasms). Curr Gastroenterol Rep. 2012; 14(6):467-72. DOI: 10.1007/s11894-012-0289-x. View

19.

Gladdy R, Strong V, Coit D, Allen P, Gerdes H, Shia J . Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009; 16(11):3154-60. DOI: 10.1245/s10434-009-0687-y. View

20.

Lamberts S, Bakker W, Reubi J, Krenning E . Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990; 323(18):1246-9. DOI: 10.1056/NEJM199011013231805. View